Phase I/IIa study of low dose subcutaneous interleukin-2 (IL-2) for treatment of refractory chronic graft versus host disease

Takeru Asano, Ken Ichi Matsuoka, Satoshi Iyama, Kazuteru Ohashi, Yoshihiro Inamoto, Chikako Ohwada, Makoto Murata, Atsushi Satake, Chikamasa Yoshida, Koichi Nakase, Yasuo Mori, Mitsune Tanimoto

    Research output: Contribution to journalArticle

    2 Citations (Scopus)

    Abstract

    Chronic graft versus host disease (cGVHD) remains a major problem for long survivors after allogeneic hematopoietic stem cell transplantation (HSCT). Currently, corticosteroid therapy is effective for cGVHD as the first line therapy. However, prolonged therapy with corticosteroids causes various severe adverse events. To develop the new therapeutic strategy of cGVHD, we have launched a multicenter phase I/IIa clinical trial of low dose subcutaneous interleukin-2 (IL-2) for treatment of steroid refractory cGVHD, which is constituted of 2 sequential phases (induction phase and maitanance phase). This study will provide the new therapeutic option for patients with refractory cGVHD after allogeneic HSCT.

    Original languageEnglish
    Pages (from-to)429-433
    Number of pages5
    JournalActa medica Okayama
    Volume70
    Issue number5
    Publication statusPublished - Jan 1 2016

    Fingerprint

    Graft vs Host Disease
    Grafts
    Refractory materials
    Interleukin-2
    Stem cells
    Hematopoietic Stem Cell Transplantation
    Adrenal Cortex Hormones
    Therapeutics
    Clinical Trials, Phase I
    Steroids
    Survivors

    All Science Journal Classification (ASJC) codes

    • Biochemistry, Genetics and Molecular Biology(all)

    Cite this

    Asano, T., Matsuoka, K. I., Iyama, S., Ohashi, K., Inamoto, Y., Ohwada, C., ... Tanimoto, M. (2016). Phase I/IIa study of low dose subcutaneous interleukin-2 (IL-2) for treatment of refractory chronic graft versus host disease. Acta medica Okayama, 70(5), 429-433.

    Phase I/IIa study of low dose subcutaneous interleukin-2 (IL-2) for treatment of refractory chronic graft versus host disease. / Asano, Takeru; Matsuoka, Ken Ichi; Iyama, Satoshi; Ohashi, Kazuteru; Inamoto, Yoshihiro; Ohwada, Chikako; Murata, Makoto; Satake, Atsushi; Yoshida, Chikamasa; Nakase, Koichi; Mori, Yasuo; Tanimoto, Mitsune.

    In: Acta medica Okayama, Vol. 70, No. 5, 01.01.2016, p. 429-433.

    Research output: Contribution to journalArticle

    Asano, T, Matsuoka, KI, Iyama, S, Ohashi, K, Inamoto, Y, Ohwada, C, Murata, M, Satake, A, Yoshida, C, Nakase, K, Mori, Y & Tanimoto, M 2016, 'Phase I/IIa study of low dose subcutaneous interleukin-2 (IL-2) for treatment of refractory chronic graft versus host disease', Acta medica Okayama, vol. 70, no. 5, pp. 429-433.
    Asano T, Matsuoka KI, Iyama S, Ohashi K, Inamoto Y, Ohwada C et al. Phase I/IIa study of low dose subcutaneous interleukin-2 (IL-2) for treatment of refractory chronic graft versus host disease. Acta medica Okayama. 2016 Jan 1;70(5):429-433.
    Asano, Takeru ; Matsuoka, Ken Ichi ; Iyama, Satoshi ; Ohashi, Kazuteru ; Inamoto, Yoshihiro ; Ohwada, Chikako ; Murata, Makoto ; Satake, Atsushi ; Yoshida, Chikamasa ; Nakase, Koichi ; Mori, Yasuo ; Tanimoto, Mitsune. / Phase I/IIa study of low dose subcutaneous interleukin-2 (IL-2) for treatment of refractory chronic graft versus host disease. In: Acta medica Okayama. 2016 ; Vol. 70, No. 5. pp. 429-433.
    @article{ee0be8568e3048c48ce20c1b8f528df5,
    title = "Phase I/IIa study of low dose subcutaneous interleukin-2 (IL-2) for treatment of refractory chronic graft versus host disease",
    abstract = "Chronic graft versus host disease (cGVHD) remains a major problem for long survivors after allogeneic hematopoietic stem cell transplantation (HSCT). Currently, corticosteroid therapy is effective for cGVHD as the first line therapy. However, prolonged therapy with corticosteroids causes various severe adverse events. To develop the new therapeutic strategy of cGVHD, we have launched a multicenter phase I/IIa clinical trial of low dose subcutaneous interleukin-2 (IL-2) for treatment of steroid refractory cGVHD, which is constituted of 2 sequential phases (induction phase and maitanance phase). This study will provide the new therapeutic option for patients with refractory cGVHD after allogeneic HSCT.",
    author = "Takeru Asano and Matsuoka, {Ken Ichi} and Satoshi Iyama and Kazuteru Ohashi and Yoshihiro Inamoto and Chikako Ohwada and Makoto Murata and Atsushi Satake and Chikamasa Yoshida and Koichi Nakase and Yasuo Mori and Mitsune Tanimoto",
    year = "2016",
    month = "1",
    day = "1",
    language = "English",
    volume = "70",
    pages = "429--433",
    journal = "Acta Medica Okayama",
    issn = "0386-300X",
    publisher = "Okayama University",
    number = "5",

    }

    TY - JOUR

    T1 - Phase I/IIa study of low dose subcutaneous interleukin-2 (IL-2) for treatment of refractory chronic graft versus host disease

    AU - Asano, Takeru

    AU - Matsuoka, Ken Ichi

    AU - Iyama, Satoshi

    AU - Ohashi, Kazuteru

    AU - Inamoto, Yoshihiro

    AU - Ohwada, Chikako

    AU - Murata, Makoto

    AU - Satake, Atsushi

    AU - Yoshida, Chikamasa

    AU - Nakase, Koichi

    AU - Mori, Yasuo

    AU - Tanimoto, Mitsune

    PY - 2016/1/1

    Y1 - 2016/1/1

    N2 - Chronic graft versus host disease (cGVHD) remains a major problem for long survivors after allogeneic hematopoietic stem cell transplantation (HSCT). Currently, corticosteroid therapy is effective for cGVHD as the first line therapy. However, prolonged therapy with corticosteroids causes various severe adverse events. To develop the new therapeutic strategy of cGVHD, we have launched a multicenter phase I/IIa clinical trial of low dose subcutaneous interleukin-2 (IL-2) for treatment of steroid refractory cGVHD, which is constituted of 2 sequential phases (induction phase and maitanance phase). This study will provide the new therapeutic option for patients with refractory cGVHD after allogeneic HSCT.

    AB - Chronic graft versus host disease (cGVHD) remains a major problem for long survivors after allogeneic hematopoietic stem cell transplantation (HSCT). Currently, corticosteroid therapy is effective for cGVHD as the first line therapy. However, prolonged therapy with corticosteroids causes various severe adverse events. To develop the new therapeutic strategy of cGVHD, we have launched a multicenter phase I/IIa clinical trial of low dose subcutaneous interleukin-2 (IL-2) for treatment of steroid refractory cGVHD, which is constituted of 2 sequential phases (induction phase and maitanance phase). This study will provide the new therapeutic option for patients with refractory cGVHD after allogeneic HSCT.

    UR - http://www.scopus.com/inward/record.url?scp=84997706260&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84997706260&partnerID=8YFLogxK

    M3 - Article

    C2 - 27777442

    AN - SCOPUS:84997706260

    VL - 70

    SP - 429

    EP - 433

    JO - Acta Medica Okayama

    JF - Acta Medica Okayama

    SN - 0386-300X

    IS - 5

    ER -